Detection of Minority Populations of HIV-1 Expressing the K103N Resistance Mutation in Patients Failing Nevirapine
- 1 January 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 38 (1) , 37-42
- https://doi.org/10.1097/00126334-200501010-00007
Abstract
Salvage therapy with efavirenz is often ineffective in patients having failed nevirapine treatment, even when mutations associated with efavirenz resistance are not detected by standard population-based genotyping. The presence of minority viral populations expressing efavirenz cross-resistance could explain these observations, and such populations were sought in plasma from patients failing nevirapine for whom genotyping revealed the presence of the Y181C mutation (usually associated with limited efavirenz cross-resistance) but not the K103N mutation (which produces high-level efavirenz resistance). Viral populations expressing K103N (>1% total virus) were detected by sequence-selective polymerase chain reaction in 4 of 16 patients failing nevirapine, although, in retrospect, the mutation was not perceptible in the original genotype in only 2 cases. Both patients with detectable K103N mutations who received efavirenz failed treatment, and virus expressing K103N emerged. Four of 5 patients without detectable K103N mutations also failed efavirenz, associated with the emergence of nonnucleoside reverse transcriptase mutations that included K103N in 2 cases. The emergence of a minority viral population expressing K103N was identified in 1 patient from a separate study group subsequent to discontinuing treatment with nevirapine. These findings support the idea that minority viral populations with distinct resistance genotypes, although undetectable by standard genotyping, can contribute to the failure of salvage regimens.Keywords
This publication has 21 references indexed in Scilit:
- Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease InhibitorsJournal of Virology, 2004
- HIV Drug ResistanceNew England Journal of Medicine, 2004
- Treatment of antiretroviral-drug-resistant HIV-1 infectionThe Lancet, 2003
- Emergence of Minor Populations of Human Immunodeficiency Virus Type 1 Carrying the M184V and L90M Mutations in Subjects Undergoing Structured Treatment InterruptionsThe Journal of Infectious Diseases, 2003
- Nevirapine or Lamivudine plus Stavudine and Indinavir: Examples of 2‐Class versus 3‐Class Regimens for the Treatment of Human Immunodeficiency Virus Type 1Clinical Infectious Diseases, 2002
- Cross-Resistance among Nonnucleoside Reverse Transcriptase Inhibitors Limits Recycling Efavirenz after Nevirapine FailureAIDS Research and Human Retroviruses, 2002
- Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral TherapyJournal of Virology, 2001
- Rapid Communication: Efavirenz- and Adefovir Dipivoxil–Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic ResponseJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Pharmacokinetics of Nevirapine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their NeonatesThe Journal of Infectious Diseases, 1998
- HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and TherapyScience, 1995